Skip to main content
Top
Published in: Trials 1/2020

Open Access 01-12-2020 | Research

The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial

Authors: Rebecca Lewis, Rachel Todd, Michelle Newton, Robert J. Jones, Caroline Wilson, Jenny L. Donovan, Richard T. Bryan, Alison Birtle, Emma Hall, on behalf of the POUT Trial Management Group

Published in: Trials | Issue 1/2020

Login to get access

Abstract

Background

The utility of patient screening logs and their impact on improving trial recruitment rates are unclear. We conducted a retrospective exploratory analysis of screening data collected within a multicentre randomised controlled trial investigating chemotherapy for upper tract urothelial carcinoma.

Methods

Participating centres maintained a record of patients meeting basic screening criteria stipulated in the trial protocol, submitting logs regularly to the clinical trial coordinating centre (CTC). Sites recorded the number of patients ineligible, not approached, declined and randomised. The CTC monitored proportions of eligible patients, approach rate (proportion of eligible patients approached) and acceptance rate (proportion recruited of those approached). Data were retrospectively analysed to identify patterns of screening activity and correlation with recruitment.

Results

Data were collected between May 2012 and August 2016, during which time 71 sites were activated—a recruitment period of 2768 centre months. A total of 1138 patients were reported on screening logs, with 2300 requests for logs sent by the CTC and 47% of expected logs received. A total of 758 patients were reported as ineligible, 36 eligible patients were not approached and 207 declined trial participation. The approach rate was 91% (344/380), and the acceptance rate was 40% (137/344); these rates remained consistent throughout the data collection. The main reason patients provided for declining (99/207, 48%) was not wanting to receive chemotherapy. There was a moderately strong correlation (r = 0.47) between the number reported on screening logs and the number recruited per site. Considerable variation in data between centres was observed, and 54/191 trial participants (28%) enrolled during this period were not reported on logs.

Conclusions

Central collection of screening logs can identify reasons for patients declining trial participation and help monitor trial activity at sites; however, obtaining complete data can be challenging. There was a correlation between the number of patients reported on logs and recruitment; however, this was likely confounded by sites’ available patient population. The use of screening logs may not be appropriate for all trials, and their use should be carefully considered in relation to the associated workload. No evidence was found that central collection of screening logs improved recruitment rates in this study, and their continued use warrants further investigation.

Trial registration

ISRCTN98387754. Registered on 31 January 2012
Literature
1.
go back to reference Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268–77.PubMedPubMedCentralCrossRef Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268–77.PubMedPubMedCentralCrossRef
2.
go back to reference Schott AF, Welch JJ, Verschraegen CF, Kurzrock R. The national clinical trials network: conducting successful clinical trials of new therapies for rare cancers. Semin Oncol. 2015;42(5):731–9.PubMedPubMedCentralCrossRef Schott AF, Welch JJ, Verschraegen CF, Kurzrock R. The national clinical trials network: conducting successful clinical trials of new therapies for rare cancers. Semin Oncol. 2015;42(5):731–9.PubMedPubMedCentralCrossRef
3.
go back to reference Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017;35(3):379–87.PubMedCrossRef Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017;35(3):379–87.PubMedCrossRef
4.
go back to reference Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer. 2009;115(6):1224–33.PubMedCrossRef Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer. 2009;115(6):1224–33.PubMedCrossRef
5.
go back to reference Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract urothelial Cell Carcinoma: 2015 update. Eur Urol. 2015;68(5):868–79.PubMedCrossRef Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract urothelial Cell Carcinoma: 2015 update. Eur Urol. 2015;68(5):868–79.PubMedCrossRef
6.
go back to reference Bower P, Brueton V, Gamble C, Treweek S, Smith CT, Young B, et al. Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities. Trials. 2014;15:399.PubMedPubMedCentralCrossRef Bower P, Brueton V, Gamble C, Treweek S, Smith CT, Young B, et al. Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities. Trials. 2014;15:399.PubMedPubMedCentralCrossRef
7.
go back to reference Tudur Smith C, Hickey H, Clarke M, Blazeby J, Williamson PR. The trials methodological research agenda: results from a priority setting exercise. Trials. 2014;15:32.PubMedPubMedCentralCrossRef Tudur Smith C, Hickey H, Clarke M, Blazeby J, Williamson PR. The trials methodological research agenda: results from a priority setting exercise. Trials. 2014;15:32.PubMedPubMedCentralCrossRef
8.
go back to reference Huddart RA, Hall E, Lewis R, Birtle A. Life and death of SPARE (Selective bladder Preservation Against Radical Excision): reflections on why the SPARE trial closed. BJU Int. 2010;106(6):753–5.PubMedCrossRef Huddart RA, Hall E, Lewis R, Birtle A. Life and death of SPARE (Selective bladder Preservation Against Radical Excision): reflections on why the SPARE trial closed. BJU Int. 2010;106(6):753–5.PubMedCrossRef
9.
go back to reference Paramasivan S, Huddart R, Hall E, Lewis R, Birtle A, Donovan JL. Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). Trials. 2011;12(1):1–15.CrossRef Paramasivan S, Huddart R, Hall E, Lewis R, Birtle A, Donovan JL. Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). Trials. 2011;12(1):1–15.CrossRef
10.
go back to reference Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006;7(2):141–8.PubMedCrossRef Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, Wilson K, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol. 2006;7(2):141–8.PubMedCrossRef
11.
go back to reference Caldwell P, Hamilton S, Tan A, Craig J. Strategies for increasing recruitment to randomized controlled trials: systematic review. PLoS Med. 2010;7(11):e1000368.PubMedPubMedCentralCrossRef Caldwell P, Hamilton S, Tan A, Craig J. Strategies for increasing recruitment to randomized controlled trials: systematic review. PLoS Med. 2010;7(11):e1000368.PubMedPubMedCentralCrossRef
12.
go back to reference Donovan JL, Rooshenas L, Jepson M, Elliott D, Wade J, Avery K, et al. Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI). Trials. 2016;17(1):283.PubMedPubMedCentralCrossRef Donovan JL, Rooshenas L, Jepson M, Elliott D, Wade J, Avery K, et al. Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI). Trials. 2016;17(1):283.PubMedPubMedCentralCrossRef
13.
go back to reference Huddart RA, Birtle A, Maynard L, Beresford M, Blazeby J, Donovan J, et al. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int. 2017;120(5):639–50.PubMedPubMedCentralCrossRef Huddart RA, Birtle A, Maynard L, Beresford M, Blazeby J, Donovan J, et al. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int. 2017;120(5):639–50.PubMedPubMedCentralCrossRef
15.
go back to reference Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, et al. Challenges and potential solutions to meeting accrual goals in a phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012;33(2):279–85.PubMedCrossRef Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, et al. Challenges and potential solutions to meeting accrual goals in a phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012;33(2):279–85.PubMedCrossRef
16.
go back to reference Mahajan P, Kulkarni A, Narayanswamy S, Dalal J, Halbe V, Patkar S, et al. Reasons why patients fail screening in Indian breast cancer trials. Perspect Clin Res. 2015;6(4):190–3.PubMedPubMedCentralCrossRef Mahajan P, Kulkarni A, Narayanswamy S, Dalal J, Halbe V, Patkar S, et al. Reasons why patients fail screening in Indian breast cancer trials. Perspect Clin Res. 2015;6(4):190–3.PubMedPubMedCentralCrossRef
17.
go back to reference Sinclair H, Batty JA, Qiu W, Kunadian V. Engaging older patients in cardiovascular research: observational analysis of the ICON-1 study. Open Heart. 2016;3(2):e000436.PubMedPubMedCentralCrossRef Sinclair H, Batty JA, Qiu W, Kunadian V. Engaging older patients in cardiovascular research: observational analysis of the ICON-1 study. Open Heart. 2016;3(2):e000436.PubMedPubMedCentralCrossRef
18.
go back to reference Slieker FJ, Kompanje EJ, Murray GD, Ohman J, Stocchetti N, Teasdale SG, et al. Importance of screening logs in clinical trials for severe traumatic brain injury. Neurosurgery. 2008;62(6):1321–8 discussion 8-9.PubMedCrossRef Slieker FJ, Kompanje EJ, Murray GD, Ohman J, Stocchetti N, Teasdale SG, et al. Importance of screening logs in clinical trials for severe traumatic brain injury. Neurosurgery. 2008;62(6):1321–8 discussion 8-9.PubMedCrossRef
19.
go back to reference Elm JJ, Palesch Y, Easton JD, Lindblad A, Barsan W, Silbergleit R, et al. Screen failure data in clinical trials: are screening logs worth it? Clin Trials (London, England). 2014;11(4):467–72.CrossRef Elm JJ, Palesch Y, Easton JD, Lindblad A, Barsan W, Silbergleit R, et al. Screen failure data in clinical trials: are screening logs worth it? Clin Trials (London, England). 2014;11(4):467–72.CrossRef
20.
21.
go back to reference Wilson C, Rooshenas L, Paramasivan S, Elliott D, Jepson M, Strong S, et al. Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. Trials. 2018;19(1):50.PubMedPubMedCentralCrossRef Wilson C, Rooshenas L, Paramasivan S, Elliott D, Jepson M, Strong S, et al. Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. Trials. 2018;19(1):50.PubMedPubMedCentralCrossRef
22.
go back to reference Wilson C, A B, Snape M, Lewis R, Hall E, Johnson M, et al., editors. Recruitment challenges for trials of rare cancers: lessons from the POUT trial for transitional cell cancer of the urinary system CRUK/11/027. Liverpool: NCRI National Cancer Conference; 2014. Wilson C, A B, Snape M, Lewis R, Hall E, Johnson M, et al., editors. Recruitment challenges for trials of rare cancers: lessons from the POUT trial for transitional cell cancer of the urinary system CRUK/11/027. Liverpool: NCRI National Cancer Conference; 2014.
23.
go back to reference Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, et al. The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30(1):81–7.PubMedCrossRef Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, et al. The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30(1):81–7.PubMedCrossRef
24.
go back to reference Pike NA, Pemberton V, Allen K, Jacobs JP, Hsu DT, Lewis AB, et al. Challenges and successes of recruitment in the “angiotensin-converting enzyme inhibition in infants with single ventricle trial” of the Pediatric Heart Network. Cardiol Young. 2013;23(2):248–57.PubMedCrossRef Pike NA, Pemberton V, Allen K, Jacobs JP, Hsu DT, Lewis AB, et al. Challenges and successes of recruitment in the “angiotensin-converting enzyme inhibition in infants with single ventricle trial” of the Pediatric Heart Network. Cardiol Young. 2013;23(2):248–57.PubMedCrossRef
25.
go back to reference Jones R, Jones RO, McCowan C, Montgomery AA, Fahey T. The external validity of published randomized controlled trials in primary care. BMC Fam Pract. 2009;10:5.PubMedPubMedCentralCrossRef Jones R, Jones RO, McCowan C, Montgomery AA, Fahey T. The external validity of published randomized controlled trials in primary care. BMC Fam Pract. 2009;10:5.PubMedPubMedCentralCrossRef
26.
go back to reference Sundaresan P, Turner S, Kneebone A, Pearse M, Fraser-Browne C, Woo HH. Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early lessons from the RAVES 0803 Trial. Clin Oncol (R Coll Radiol). 2014;26(6):348–52.CrossRef Sundaresan P, Turner S, Kneebone A, Pearse M, Fraser-Browne C, Woo HH. Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early lessons from the RAVES 0803 Trial. Clin Oncol (R Coll Radiol). 2014;26(6):348–52.CrossRef
27.
go back to reference Fayter D, McDaid C, Eastwood A. A systematic review highlights threats to validity in studies of barriers to cancer trial participation. J Clin Epidemiol. 2007;60(10):990–1001.PubMedCrossRef Fayter D, McDaid C, Eastwood A. A systematic review highlights threats to validity in studies of barriers to cancer trial participation. J Clin Epidemiol. 2007;60(10):990–1001.PubMedCrossRef
28.
go back to reference Lemieux J, Forget G, Brochu O, Provencher L, Cantin G, Desbiens C, et al. Evaluation of eligibility and recruitment in breast cancer clinical trials. Breast. 2014;23(4):385–92.PubMedCrossRef Lemieux J, Forget G, Brochu O, Provencher L, Cantin G, Desbiens C, et al. Evaluation of eligibility and recruitment in breast cancer clinical trials. Breast. 2014;23(4):385–92.PubMedCrossRef
29.
go back to reference St Germain D, Denicoff AM, Dimond EP, Carrigan A, Enos RA, Gonzalez MM, et al. Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual. J Oncol Pract. 2014;10(2):e73–80.PubMedPubMedCentralCrossRef St Germain D, Denicoff AM, Dimond EP, Carrigan A, Enos RA, Gonzalez MM, et al. Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual. J Oncol Pract. 2014;10(2):e73–80.PubMedPubMedCentralCrossRef
Metadata
Title
The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial
Authors
Rebecca Lewis
Rachel Todd
Michelle Newton
Robert J. Jones
Caroline Wilson
Jenny L. Donovan
Richard T. Bryan
Alison Birtle
Emma Hall
on behalf of the POUT Trial Management Group
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-020-04559-w

Other articles of this Issue 1/2020

Trials 1/2020 Go to the issue